Navigation Links
Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Date:11/9/2009

Once-daily INTUNIV is now available in US pharmacies in four dosage strengths (1 mg, 2 mg, 3 mg, and 4 mg) and is marketed in the United States by the existing Shire ADHD sales team of nearly 600 representatives. INTUNIV is not a controlled substance and has no known potential for abuse or dependence.

"INTUNIV is the newest ADHD treatment to receive FDA approval and the latest addition to the Shire ADHD portfolio. The availability of INTUNIV now allows physicians to prescribe the first and only nonscheduled alpha-2A receptor agonist indicated for the treatment of ADHD to help their patients manage a range of ADHD symptoms," said Michael Yasick, Senior Vice President of the ADHD Business Unit at Shire. "Shire is proud to provide physicians and the ADHD community with a novel treatment choice, which expands the range of available treatment options, allowing physicians to optimize the management of ADHD."

The commitment of Shire to making INTUNIV available for ADHD patients is consistent with the company's strategy to expand and diversify its ADHD portfolio, which now consists of four ADHD treatment options of scheduled and nonscheduled medicines in the United States and three medicines approved for the treatment of ADHD outside the United States.

About INTUNIV

The efficacy of INTUNIV in the treatment of ADHD was established in two, similarly designed, placebo-controlled clinical trials in children and adolescents aged 6 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV®) criteria for ADHD. Statistically significant improvements were reported by investigators, parents, and teachers.

The first pivotal trial was a phase III, double-blind, parallel-group trial, in which investigators randomized 345 children aged 6 to 17 years to either
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
2. New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners ADHD Rating Scale
3. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
4. Shire Announces FDA Approval of Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
5. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
6. Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing
7. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
8. New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
9. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
10. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
11. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 21, 2014  Alere Inc. (NYSE: ... diagnostic tests, has appointed Juliet Cunningham as ... Cunningham will be responsible for driving communications with the ... on a series of changes to increase shareholder value, ... to investors," said Namal Nawana, Chief Executive Officer. "We ...
(Date:11/21/2014)... 2014 In September 2014, the staff at ... a new product development plan that started with the ... lab coat , aptly named "Vera G.," after ... the world. The new women,s designer lab coat is ... sleek envelope collar, vertical princess and high waist seaming, ...
(Date:11/21/2014)... , Nov. 21, 2014  Abaxis, Inc. (NasdaqGS: ... instruments and consumables for the medical, research, and veterinary ... veterinary and research markets in the United ... stock purchase agreement to acquire 100% of QCR & ... based distribution organization. The transaction closed on November ...
Breaking Medicine Technology:Alere Appoints Juliet Cunningham to Lead Investor Relations 2Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
(Date:11/22/2014)... November 22, 2014 Setria® Glutathione ... (TGA) approved it for use “as a therapeutically ... listed within the Therapeutic Goods (Listing) Notice 2014 ... Kyowa Hakko’s Setria® Glutathione will be exclusivity distributed ... that sources and imports fine chemicals to Australian ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Nocturia ... as the complaint that the individual has to ... voiding. The report “Nocturia – Pipeline Review, H2 ... for Nocturia, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:11/22/2014)... 22, 2014 (HealthDay News) -- The wide variety and ... a threat for people with food allergies, an expert ... so many types of food allergies that it can ... holidays," Dr. Guha Krishnaswamy, director of allergy and clinical ... a hospital news release. "If you know you ...
(Date:11/22/2014)... 2014 Hastings and Hastings, a discount ... announces providing clients with the option of leaving an ... a flexible, intuitive and easy to navigate website that ... to Google + allows clients to research the Hastings ... more informed decision when retaining an attorney. Those who ...
(Date:11/22/2014)... Boulder, CO (PRWEB) November 22, 2014 ... on growth equity investments in the consumer brand ... LLC. The investment will be used to help ... new product pipeline rollout, particularly its proprietary apparel ... Suslow will join BackJoy’s Board of Directors. , ...
Breaking Medicine News(10 mins):Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 2Health News:Hastings and Hastings Announces Providing Clients with the Option of Leaving an Online Review Using Google + 3Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3
... the sleep disturbances, study finds , WEDNESDAY, Dec. 2 (HealthDay ... increase the risk of sleep apnea, say U.S. researchers. , ... damages the brain and can cause immediate and dangerous problems ... the Johns Hopkins School of Medicine in Baltimore, said in ...
... say , WEDNESDAY, Dec. 2 (HealthDay News) -- New research ... in the lives of people with Fabry disease, a rare ... The progressive disease, linked to the lack of an enzyme ... fatal because it boosts the risk for a stroke, heart ...
... 2 Huntington Memorial Hospital,s stroke program has received ... designating the hospital a primary stroke center. This ... center" hospitals throughout Los Angeles County. , ... more important, a wonderful benefit for Pasadena and its ...
... SAN FRANCISCO, Dec. 2 In the wake of the ... plastics chemical linked to birth defects and breast cancer, Congress ... House and Senate are considering bills to ban bisphenol A, ... Sen. Dianne Feinstein of California and Rep. Edward Markey of ...
... , ... , WASHINGTON, Dec. 2 The membership of the National Quality ... and reappointed four current Board members. The new Board members represent ... suppliers, and public and community healthcare. , The newly elected ...
... , NEW YORK, Dec. 2 Care ... Advanced Illness Coordinated Care (AICC) , has been shown to reduce ... the quality of life for seniors and their family caregivers without ... published in American Journal of Managed Care (November 2009). ...
Cached Medicine News:Health News:Ecstasy Users at Higher Risk of Sleep Apnea 2Health News:Huntington Hospital Earns Designation as Primary Stroke Center 2Health News:Pre-Polluted Babies: Congress Must Act to Protect Infants, Moms from Toxic Plastics Chemical BPA 2Health News:National Quality Forum Members Elect Nine Directors to Board 2Health News:National Quality Forum Members Elect Nine Directors to Board 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 2Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 3Health News:Outpatient Palliative Care Reduces Hospitalizations, Which Impact Costs, While Improving Quality of Life for Seniors and Family Caregivers - New Study in American Journal of Managed Care 4
... The challenge for Carl Zeiss was ... on the eye and for preoperative ... result of this development work is ... revolutionizing all previous techniques and setting ...
Ahmed Glaucoma Valve (small size) with Pars Plana Clip ....
Ahmed Glaucoma Valve....
... biocompatibility is established. Provides a robust and ... correct positioning on the globe. Pressure Ridge ... when covered by Tenons tissue, acts as ... hypotony. The range of implants allows the ...
Medicine Products: